BRCA1 and breast cancer: In the present study, we have employed approaches previously developed by the ENIGMA consortia [5] to perform a comprehensive characterization of AS at the BRCA1 locus in a cohort of 70 breast tumor samples from patients diagnosed as having locally advanced breast cancer, enrolled in a neoadjuvant clinical trial and whose tumors have been classified into intrinsic subtypes.